본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Journal of autoimmunity v.85, 2017년, pp.103 - 116   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Novel therapeutic targets for inflammatory bowel disease

Argollo, Marjorie (Department of Gastroenterology, Universidade Federal de São Paulo, São Paulo, Brazil ) ; Fiorino, Gionata (IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy ) ; Hindryckx, Pieter (Department of Gastroenterology, University Hospital of Ghent, Ghent, Belgium ) ; Peyrin-Biroulet, Laurent (Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre, France ) ; Danese, Silvio (IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy ) ;
  • 초록  

    Abstract Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), are immune mediated conditions associated with progressive damage of the inflamed gut tissue, and have a considerable impact on the patient's quality of life. The pathogenesis remains uncertain, but it is clear that complex mechanisms associated with host and luminal factors are involved, generating an unbalance between pro- and anti-inflammatory signaling. It is well established that the purpose of an adequate and complete control of the intestinal inflammation measured not only by clinical symptoms, but also with more objective data such as fecal biomarkers (calprotectin) and endoscopy. The treat to target approach possibly correlates with minor risk for complications associated with IBD, specially surgery and cancer. The most studied inflammatory pathway in IBD, is described to be dependent of the pro-inflammatory cytokine tumor necrosis factor-alfa (TNF-α), and compose the first line studies for development of biological drugs, in this case, targeting specifically the action of TNF-α. Even though, the use of anti-TNFs drugs are associated with improvement of the inflammation in some patients, a great portion do not respond at first or lose response over time. These findings made clear about the possibility of other mechanisms involved in perpetuating the chronic inflammatory state. Many years of intensive research have led to the identification of different inflammatory pathways that form the basis of the intensive drug development that we are experiencing today. These novel drugs include agents that target leukocyte trafficking, Interleukin (IL) 23, Janus kinases (JAK), Sphingosine 1 phosphate (S1P) and Smad7, an inhibitor of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1). In this manuscript, we aim to review the most promising late-stage drug candidates for the treatment of IBD. Highlights Anti-TNF therapy remains an effective and safe tool in IBD, however, a substantial portion of patients show lack of response. Anti-adhesion drugs are effective and safe gut-selective agents that have shown a salutary potential in the treatment in IBD. Anti-IL-23 and other cytokine blockers are expected to be a valid alternative to anti-TNF in managing IBD patients. Novel therapeutic molecules that target different inflammatory pathways and signaling may constitute a powerful alternative in the management of IBD.


  • 주제어

    Inflammatory bowel disease .   Biologics .   Anti-adhesion molecules .   Anti-cytokine .   Small molecules drugs.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기